A5047670085- Multiple Sclerosis Research Studies
- Peripheral Neuropathies and Disorders
- Rheumatoid Arthritis Research and Therapies
- Polyomavirus and related diseases
- Botulinum Toxin and Related Neurological Disorders
- Cardiovascular Syncope and Autonomic Disorders
- Amyotrophic Lateral Sclerosis Research
- Neurosurgical Procedures and Complications
- Cerebral Venous Sinus Thrombosis
- Infectious Encephalopathies and Encephalitis
- Delphi Technique in Research
- Systemic Sclerosis and Related Diseases
- Thermal Regulation in Medicine
- Privacy-Preserving Technologies in Data
- Intracranial Aneurysms: Treatment and Complications
- Digital Mental Health Interventions
- Lymphadenopathy Diagnosis and Analysis
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Reproductive System and Pregnancy
- Neurology and Historical Studies
- Neurogenesis and neuroplasticity mechanisms
- Long-Term Effects of COVID-19
- Liver Disease and Transplantation
- Cytokine Signaling Pathways and Interactions
- Face recognition and analysis
Amphia Ziekenhuis
2019-2025
Amsterdam Neuroscience
2017-2023
Amsterdam University Medical Centers
2019-2023
Vrije Universiteit Amsterdam
2022
Neurology, Inc
2017-2019
Amsterdam UMC Location Vrije Universiteit Amsterdam
2017-2018
University Medical Center
2017
University Hospital and Clinics
2017
Sanquin
2017
Morriston Hospital
2017
To describe a series of patients with relapsing multiple sclerosis (MS) who experienced significant and unexpected disease activity within the first 12 months after switching from fingolimod to alemtuzumab.Patients MS treated sequentially then alemtuzumab subsequent were identified by personal communication 6 different European neuroscience centers.Nine identified. Median duration treatment was 94 (39-215) follow-up time cycle 20 (14-21) months. Following infusion cycle, 8 at least 1...
Extended interval dosing (EID) of natalizumab is a promising strategy to optimise treatment in multiple sclerosis (MS). Personalised EID by therapeutic drug monitoring can enable further extension intervals.
Background Natalizumab is a highly effective drug for patients with relapsing-remitting multiple sclerosis (MS). A disadvantage of this treatment the risk progressive multifocal leukoencephalopathy in who are seropositive John Cunningham virus (JCV). JCV seroconversion rates increase under natalizumab compared non-natalizumab using controls. The aim study was to assess whether lower trough concentrations associated reduced higher concentrations. Methods Two overlapping cohorts treated...
Importance Increasing numbers of people with multiple sclerosis (MS) use disease-modifying therapy (DMT). Long-term stable disease while taking such medications provides a rationale for considering DMT discontinuation given patient burden, costs, and potential adverse effects immunomodulating therapy. Objective To investigate whether first-line can be safely discontinued in patients long-term MS. Design, Setting, Participants This multicenter, rater-blinded, noninferiority randomized...
The high incidence of aneurysmal subarachnoid hemorrhage (aSAH) in Finland may be related to genetic or environmental factors, which also influence patient and aneurysm characteristics. We compared these characteristics 2 cohorts (Kuopio) the Netherlands (Utrecht).For aSAH patients Kuopio (n=1786) Utrecht (n=1788), we sex, age at onset, sites number aneurysms from 1986 2005. Five-year time trends were assessed with chi(2) tests (sex distribution aneurysms) 1-way ANOVA (age).The proportion...
To investigate disease activity and disability progression following pregnancy-related discontinuation of natalizumab (NTZ) in patients with relapsing-remitting MS.A retrospective cohort study clinical radiologic data who discontinued NTZ for reasons.Twenty-two discontinuations 17 were evaluated. The median time to conception was 3.4 months. Relapses more frequent whom did not occur within 6 months (p = 0.022). Confirmed occurred 27.3% associated < 0.001).Early after is a reduced risk...
Background: Accurate clinical assessment in multiple sclerosis (MS) is challenging. The Assess MS system being developed to automatically quantify motor dysfunction MS, including upper extremity function (UEF) and mobility. Objective: To determine what extent combinations of standardized movements included the explain accepted measures UEF Methods: patients were recruited at four European centres. Eight selected, tasks activities daily living (ADL) classical neurological tests. Movements...
Background: The Arm Function in Multiple Sclerosis Questionnaire (AMSQ) has been developed to assess upper extremity function of patients with multiple sclerosis (MS). A minimal clinically important difference (MCID) value not determined yet. Objective: objective this study is determine an MCID for AMSQ. Methods: We used the sensitivity- and specificity-based approach dichotomized global perceived effect as anchor. Results: receiver operating characteristic (ROC) curve yielded optimal...
Background: Biomarkers of neuronal and axonal damage (serum neurofilament light (sNfL) serum glial fibrillary acidic protein (sGFAP)) may provide insight into the aetiology natalizumab wearing-off symptoms (WoSs). Objectives: We investigated longitudinal association between predictive value sNfL sGFAP occurrence WoS in MS patients treated with natalizumab. Methods: performed measurements NEXT-MS trial participants who completed a questionnaire about WoS. Results: A total 364 were included....
In chronic neurological diseases, especially in multiple sclerosis (MS), clinical assessment of motor dysfunction is crucial to monitor the disease patients. Traditional scales are not sensitive enough detect slight changes. Video recordings patient performance more accurate and increase reliability severity ratings. When these automated, quantitative disability assessments by machine learning algorithms can be created. Creation involves non-health care professionals, which a challenge for...
Motor dysfunction, particularly ataxia, is one of the predominant clinical manifestations in patients with multiple sclerosis (MS). Assessment motor dysfunction suffers from a high variability. We investigated whether rating ataxia can be improved through use reference videos, covering spectrum severity degrees as defined Neurostatus-Expanded Disability Status Scale. Twenty-five neurologists participated. The variability their assessments was significantly lower when videos were used (SD =...
Objective: To test whether coded frame vectors of autoencoders contain relevant information to analyse videos patient movements and preserve data privacy. Background: Clinical assessment disability, especially motor dysfunction, is crucial monitor patient’s disease. Video recordings performances are used increase reliability in severity ratings. These would allow automated, quantitative disability assessments by machine learning algorithms. However, creation these algorithms usually involves...
Background and objectivesWearing-off symptoms during natalizumab treatment in multiple sclerosis are characterized by an increase of MS-related prior to administration. The influence extended interval dosing (EID) on wearing-off important consider, as this might cause hesitancy initiating or continuing EID.MethodsParticipants the NEXT-MS trial, which intervals adjusted based drug concentrations, were divided into two groups: group containing participants with at least one week additional...
Upper extremity function (UEF) is often compromised in multiple sclerosis (MS), although its importance regularly underrecognized relative to ambulation. We explored the concurrent presence of impairment UEF and ambulation by examining various aspects across different levels ambulation.The cohort consisted 247 patients with clinically definite MS or isolated syndrome according revised 2010 McDonald criteria. The Nine-Hole Peg Test Expanded Disability Status Scale were used stratify into...
Aim: To gain insight into current treatment and barriers to optimal for high disease activity relapsing remitting multiple sclerosis (MS) in the Netherlands. Materials & methods: A two-round Delphi panel using an online questionnaire was conducted. Seven MS neurologists from diverse locations Netherlands were invited participate. Result: Out of seven neurologists, five completed both rounds. Conclusion: Effectiveness side effects along with patient's lesion load most important factors...